Legal & General Group Plc Has $84.58 Million Stake in United Therapeutics Corporation $UTHR

Legal & General Group Plc trimmed its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 13.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 173,592 shares of the biotechnology company’s stock after selling 26,064 shares during the period. Legal & General Group Plc’s holdings in United Therapeutics were worth $84,583,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Clearstead Advisors LLC increased its holdings in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares during the last quarter. Independent Advisor Alliance increased its holdings in United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the last quarter. Bessemer Group Inc. increased its holdings in United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after buying an additional 28 shares during the last quarter. Archer Investment Corp boosted its position in United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 31 shares during the period. Finally, Signaturefd LLC boosted its position in United Therapeutics by 4.1% during the fourth quarter. Signaturefd LLC now owns 896 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 35 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $562.82, for a total transaction of $4,671,406.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $25,423,705.04. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $565.63, for a total transaction of $5,656,300.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,676,831.88. This represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 601,473 shares of company stock valued at $337,090,644 over the last quarter. 8.60% of the stock is owned by company insiders.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
• Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
• Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
• Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $556.82 on Friday. The firm has a 50-day moving average of $566.51 and a 200-day moving average of $515.84. The stock has a market cap of $23.64 billion, a PE ratio of 20.55, a PEG ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period in the previous year, the firm posted $6.63 EPS. The company’s revenue was down 1.6% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Corporation will post 26.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HC Wainwright lifted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Raymond James Financial assumed coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Finally, Bank of America lifted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.